On this video, Ursula A. Matulonis, MD, discusses outcomes from the part 3 MIRASOL trial of mirvetuximab soravtansine-gynx for sufferers with folate receptor alpha-positive, platinum-resistant ovarian most cancers.
Outcomes of the trial, which evaluated the efficacy and security of mirvetuximab soravtansine-gynx (Elahere, AbbVie), had been introduced at Society of Gynecologic Oncology Annual Assembly on Girls’s Most cancers.
“The median general survival for sufferers receiving mirvetuximab was 16.85 months vs. 13.34 months for investigator’s alternative chemotherapy, with a hazard ratio of 0.68,” Matulonis, chief of the division of gynecologic oncology at Dana-Farber Most cancers Institute and professor at Harvard Medical College, stated. “The ultimate median PFS for mirvetuximab was 5.59 months vs. 3.98 months for investigator’s alternative chemotherapy.”
Sources/Disclosures
Collapse
Supply:
Healio interviews
Disclosures:
Matulonis experiences consulting charges from Merck; knowledge security monitoring board participation for Mural Oncology and Symphogen; and scientific advisory board participation for Abbvie, Allarity, Daiichi Sankyo, Eisai, GSK, Immunogen, NextCure, Novartis, Profound Bio, Tango Therapeutics and the Ovarian Most cancers Analysis Alliance.
